Soluble tumor necrosis factor receptor type II in the early diagnosis of fever in neutropenia.

Abstract

Sepsis in chemotherapy-associated neutropenia is a major cause of mortality in the treatment of acute myeloid leukemia (AML). Early diagnosis of sepsis is crucial for patient survival. We analyzed the value of prospectively measuring serum concentrations of soluble tumor necrosis factor receptor type II (sTNF-RII) in patients with AML for early diagnosis of sepsis in neutropenia. Therefore, 54 adult patients with AML and neutropenia were followed around the onset of fever. A total of 59 febrile episodes were documented. We could not demonstrate a significant increase in sTNF-RII levels prior to fever. sTNF-RII concentrations were not predictive of the severity of a febrile episode. Based on these data, we cannot recommend the routine screening of sTNF-RII for early detection of septic complications in patients undergoing cytoreductive therapy of AML.

• Authors: M Goetz, G Behre, G Heussel, H T Steinmetz, A Eigler, W Hiddemann, M Weiss
• Journal: Annals of hematology (Ann Hematol) Vol. 81 Issue 7 Pg. 382-5 (Jul 2002) ISSN: 0939-5555 [Print] Germany
• PMID: 12185508 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Antigens, CD
• Receptors, Tumor Necrosis Factor
• Receptors, Tumor Necrosis Factor, Type II

Topics

• Acute Disease
• Adult
• Aged
• Antigens, CD (analysis)
• Female
• Fever (metabolism, microbiology, physiopathology)
• Humans
• Infections (complications, diagnosis)
• Leukemia, Myeloid (surgery)
• Male
• Middle Aged
• Neutropenia (complications)
• Osmolar Concentration
• Pilot Projects
• Prospective Studies
• Receptors, Tumor Necrosis Factor (analysis)
• Receptors, Tumor Necrosis Factor, Type II
• Severity of Illness Index
• Solubility
• Time Factors